Measurement of primary hemostasis potential with platelet function analyzer to investigate the predictive effect on post-operative blood loss in cyanotic and acyanotic pediatric patients

Mehmet Şanser Ateş, (Koç Üniversitesi, Tıp Fakültesi, Kalp Damar Cerrahisi Anabilim Dalı, İstanbul, Türkiye)
ATIF AKCEVIN, (Koç Üniversitesi, Tıp Fakültesi, Kalp Damar Cerrahisi Anabilim Dalı, İstanbul, Türkiye)
Oğuzhan ŞAL, (İstanbul Üniversitesi, Tıp Fakültesi, Kalp ve Damar Cerrahisi Anabilim Dalı, İstanbul, Türkiye)
Zafer Cengiz ER, (Bozok Üniversitesi, Tıp Fakültesi, Kalp ve Damar Cerrahisi Anabilim Dalı, Yozgat, Türkiye)
Alper İbrahim TOSYA (Koç Üniversitesi, Tıp Fakültesi, Kalp Damar Cerrahisi Anabilim Dalı, İstanbul, Türkiye)
Experimental Biomedical Research
8 0
Yıl: 2023 Cilt: 6 Sayı: 3 Sayfa Aralığı: 168 - 180 Metin Dili: İngilizce DOI: 10.30714/j-ebr.2023.181 İndeks Tarihi: 21-07-2023

Measurement of primary hemostasis potential with platelet function analyzer to investigate the predictive effect on post-operative blood loss in cyanotic and acyanotic pediatric patients

Öz:
Aim: To investigate hemostatic parameters, including primary hemostasis potential in twenty pediatric patients with or without cyanosis undergoing cardio-pulmonary bypass (CPB) and cardiac surgery to repair congenital defects. Methods: The platelet function analyzer is an instrument that provides a rapid, in vitro, quantitative measurement of platelet adhesion and aggregation in whole blood flowing through a small aperture under high shear conditions. Other parameters monitored included blood loss, prothrombin time, anti-thrombin 3 activity, and fibrinogen and D-dimer levels. Additionally, hematocrit and albumin levels were monitored to assess the level of hemodilution during CPB. Results: Both, cyanotic and acyanotic pediatric patients had evidence of supranormal primary hemostasis potential. Although, measurements in cyanotic patients exhibited a higher percentage ratio, this was found to be statistically insignificant between cyanotic and acyanotic patients (collagen-epinephrine p=0.07 and, collagen and adenosine diphosphate (ADP) p=0.248). While, in preoperative period, measurements of primary hemostasis potential, coagulation and fibrinolytic system parameters demonstrated no statistically significant difference between cyanotic and acyanotic patients, measurement of prothrombin time, international normalized ratio and thrombin time levels significantly changed in cyanotic patients, after the operation (p<0,05). Longer cardio-pulmonary bypass time in cyanotic patients could be responsible for this indifference. Conclusion: The results of our study suggest that the platelet function analyzer system may be an indicator that it can predict bleeding in the postoperative period.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • [1] Xu JJ, Han MJ, Jiang YJ, et al. Prevention and control of HIV/AIDS in China: lessons from the past three decades. Chin Med J (Engl). 2021; 134(23): 2799-2809.
  • [2] Govender RD, Hashim MJ, Khan MA, et al. Global Epidemiology of HIV/AIDS: A Resurgence in North America and Europe. J Epidemiol Glob Health. 2021;11(3): 296-301.
  • [3] Brooks JT, Buchacz K, Gebo KA, et al. HIV Infection and Older Americans: The Public Health Perspective. Am J Public Health. 2012; 102(8): 1516-1526.
  • [4] He Y, Lu H. Clinical guidelines for the diagnosis and treatment of HIV/AIDS in China: Their potential benefits and impact on public health. Biosci Trends. 2022; 15(6): 413-417.
  • [5] Kaya N. Analysis of HIV/AIDS Reports in Turkey from Disaster Management Perspective. Journal of International Health Sciences and Management. 2021; 7(14): 46- 52.
  • [6] Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013; 173(8): 614-622.
  • [7] Marcus JL, Chao CR, Leyden WA, et al. Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care. J Acquir Immune Defic Syndr. 2016; 73(1): 39-46.
  • [8] Helleberg M, May MT, Ingle SM, et al. Smoking and life expectancy among HIVinfected individuals on antiretroviral therapy in Europe and North America. AIDS. 2015; 29(2): 221-229.
  • [9] Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011; 62: 141-155.
  • [10] Yasar KK, Kehribar HA, Kasıkçi H, et al. Analysis of HIV RNA Results in HIV/AIDS Patients. Med Bull Haseki 2014; 52: 80-83.
  • [11] Anyimadu H, Pingili C, Sivapalan V, et al. The Impact of Absolute CD4 Count and Percentage Discordance on Pneumocystis Jirovecii Pneumonia Prophylaxis in HIVInfected Patients. J Int Assoc Provid AIDS Care. 2018;17: 2325958218759199.
  • [12] Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord, Young J, Psichogiou M, Meyer L, et al. CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med. 2012; 9(3): 31001194.
  • [13] De Biasi S, Bianchini E, Nasi M, et al. Th1 and Th17 proinflammatory profile characterizes invariant natural killer T cells in virologically suppressed HIV+ patients with low CD4+/CD8+ ratio. AIDS. 2016; 30: 2599-2610.
  • [14] Castilho JL, Shepherd BE, Koethe J, et al. CD4+/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy. AIDS. 2016; 30(6): 899-908.
  • [15] https://hsgm.saglik.gov.tr/tr/haberler/t%C3% BCrkiye-h%C4%B1v-a%C4%B1ds-kontrolprogram% C4%B1-ve-h%C4%B1va% C4%B1ds-tan%C4%B1-tedavirehberi. html
  • [16] Nakagawa F, May M, Phillips A. Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis. 2013; 26(1): 7-25.
  • [17] Phillips AN, Staszewski S, Weber R, et al. HIV viral response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001; 286: 2560-2567.
  • [18] Bradley H, Hall HI, Wolitski RJ, et al. Vital Signs:HIV diagnosis, care and treatment among persons living with HIV-United States, 2011. MMWR Morb Mortal Wkly Rep. 2014; 63(47):1113-1117.
  • [19] Schouten J, Wit FW, Stolte IG, et al.; AGEhIV Cohort Study Group. Crosssectional comparison of the prevalence of ageassociated comorbidities and their risk factors between HIV-infected and uninfected individuals: the age H IV cohort study. Clin Infect Dis. 2014; 59(12):1787-1797.
  • [20] Boyd MA. Current and future management of treatment failure in low- and middle-income countries. Curr Opin HIV AIDS. 2010; 5(1): 83-89.
  • [21] Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112(5):1557-1569.
  • [22] McBride JA, Striker R. Imbalance in the game of T cells: What can the CD4/CD8 T-cell ratio tell us about HIV and health?. PLoS Pathog. 2017;13(11): e1006624.
  • [23] La Gruta NL, Thomas PG. Interrogating the relationship between naïve and immune antiviral T cell repertoires. Curr Opin Virol. 2013; 3(4): 447-451.
  • [24] Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation and HIV disease. Trends Microbiol. 2013; 21(1): 6-13.
  • [25] Wikby A, Månsson IA, Johansson B, et al. The immune-risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20-100 years of age. Biogerontology. 2008; 9: 299-308.
  • [26] Margolick JB, Muñoz A, Donnenberg AD, et al. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS Cohort Study. Nat Med 1995:1(7): 674-680.
  • [27] Strindhall J, Skog M, Ernerudh J, et al. The inverted CD4/CD8 ratio and associated parameters in 66-year-old individuals: the Swedish HEXA immune study. Age. 2013; 35(3): 985-991.
  • [28] Serrano-Villar S, Pérez-Elías MJ, Dronda F, et al. Increased risk of serious non-AIDSrelated events in HIV-infected subjects on antiretroviral therapy associated with a low CD4/CD8 ratio. PloS one. 2014; 9(1): e85798.
  • [29] Monsalvo M, Vallejo A, Fontecha M, et al. CD4/CD8 ratio improvement in HIV-1- infected patients receiving dual antiretroviral treatment. Int J STD AIDS. 2019; 30(7): 656- 662.
  • [30] Helleberg M, Kronborg G, Ullum H, et al. Course and Clinical Significance of CD8+ TCell Counts in a Large Cohort of HIVInfected Individuals. J Infect Dis. 2015; 211(11): 1726-1734.
  • [31] Mutoh Y, Nishijima T, Inaba Y, et al. Incomplete Recovery of CD4 Cell Count, CD4 Percentage, and CD4/CD8 Ratio in Patients With Human Immunodeficiency Virus Infection and Suppressed Viremia During Long-term Antiretroviral Therapy. Clin Infect Dis. 2018; 67(6): 927-933.
  • [32] Milanés-Guisado Y, Gutiérrez-Valencia A, Trujillo-Rodríguez M, et al. Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIVinfected patients on treatment. PLoS One. 2018; 13(10): e0205777.
  • [33] Doganer IF, Tabak FA, Us T. The Incidence Rate of Confirmed Real HIV Pozitivity in Eskisehir Region. T Tıp Öğr Arş D. 2019; 1 (3) : 73-77.
  • [34] Sargin F, Goktas S. HIV prevalence among men who have sex with men in Istanbul nt J Infect Dis. 2017; 54:58-61.
  • [35] Gezer Y, Toplu SA, Yuksel M, et al. Evaluation of CD4/CD8 ratio in treatment follow-up of patients with HIV diagnois in an infection clinic. Ann Med Res. 2022; 29(7): 743-747.
  • [36] Çerçi P, İnkaya AÇ, Alp Ş, Tümer A, Ünal S. [Evaluation of 255 HIV/AIDS cases: Hacettepe cohort, Ankara, Turkey]. Mikrobiyol Bul. 2016 Jan;50(1):94-103.
  • [37] Yemisen M, Aydın OA, Gunduz A, et al. Epidemiological profile of naive HIV-1/AIDS patients in Istanbul: the largest case series from Turkey. Curr HIV Res. 2014;12(1):60- 64.
APA Ateş M, AKCEVIN A, Şal O, ER Z, TOSYA A (2023). Measurement of primary hemostasis potential with platelet function analyzer to investigate the predictive effect on post-operative blood loss in cyanotic and acyanotic pediatric patients. , 168 - 180. 10.30714/j-ebr.2023.181
Chicago Ateş Mehmet Şanser,AKCEVIN ATIF,Şal Oğuzhan,ER Zafer Cengiz,TOSYA ALPER IBRAHIM Measurement of primary hemostasis potential with platelet function analyzer to investigate the predictive effect on post-operative blood loss in cyanotic and acyanotic pediatric patients. (2023): 168 - 180. 10.30714/j-ebr.2023.181
MLA Ateş Mehmet Şanser,AKCEVIN ATIF,Şal Oğuzhan,ER Zafer Cengiz,TOSYA ALPER IBRAHIM Measurement of primary hemostasis potential with platelet function analyzer to investigate the predictive effect on post-operative blood loss in cyanotic and acyanotic pediatric patients. , 2023, ss.168 - 180. 10.30714/j-ebr.2023.181
AMA Ateş M,AKCEVIN A,Şal O,ER Z,TOSYA A Measurement of primary hemostasis potential with platelet function analyzer to investigate the predictive effect on post-operative blood loss in cyanotic and acyanotic pediatric patients. . 2023; 168 - 180. 10.30714/j-ebr.2023.181
Vancouver Ateş M,AKCEVIN A,Şal O,ER Z,TOSYA A Measurement of primary hemostasis potential with platelet function analyzer to investigate the predictive effect on post-operative blood loss in cyanotic and acyanotic pediatric patients. . 2023; 168 - 180. 10.30714/j-ebr.2023.181
IEEE Ateş M,AKCEVIN A,Şal O,ER Z,TOSYA A "Measurement of primary hemostasis potential with platelet function analyzer to investigate the predictive effect on post-operative blood loss in cyanotic and acyanotic pediatric patients." , ss.168 - 180, 2023. 10.30714/j-ebr.2023.181
ISNAD Ateş, Mehmet Şanser vd. "Measurement of primary hemostasis potential with platelet function analyzer to investigate the predictive effect on post-operative blood loss in cyanotic and acyanotic pediatric patients". (2023), 168-180. https://doi.org/10.30714/j-ebr.2023.181
APA Ateş M, AKCEVIN A, Şal O, ER Z, TOSYA A (2023). Measurement of primary hemostasis potential with platelet function analyzer to investigate the predictive effect on post-operative blood loss in cyanotic and acyanotic pediatric patients. Experimental Biomedical Research, 6(3), 168 - 180. 10.30714/j-ebr.2023.181
Chicago Ateş Mehmet Şanser,AKCEVIN ATIF,Şal Oğuzhan,ER Zafer Cengiz,TOSYA ALPER IBRAHIM Measurement of primary hemostasis potential with platelet function analyzer to investigate the predictive effect on post-operative blood loss in cyanotic and acyanotic pediatric patients. Experimental Biomedical Research 6, no.3 (2023): 168 - 180. 10.30714/j-ebr.2023.181
MLA Ateş Mehmet Şanser,AKCEVIN ATIF,Şal Oğuzhan,ER Zafer Cengiz,TOSYA ALPER IBRAHIM Measurement of primary hemostasis potential with platelet function analyzer to investigate the predictive effect on post-operative blood loss in cyanotic and acyanotic pediatric patients. Experimental Biomedical Research, vol.6, no.3, 2023, ss.168 - 180. 10.30714/j-ebr.2023.181
AMA Ateş M,AKCEVIN A,Şal O,ER Z,TOSYA A Measurement of primary hemostasis potential with platelet function analyzer to investigate the predictive effect on post-operative blood loss in cyanotic and acyanotic pediatric patients. Experimental Biomedical Research. 2023; 6(3): 168 - 180. 10.30714/j-ebr.2023.181
Vancouver Ateş M,AKCEVIN A,Şal O,ER Z,TOSYA A Measurement of primary hemostasis potential with platelet function analyzer to investigate the predictive effect on post-operative blood loss in cyanotic and acyanotic pediatric patients. Experimental Biomedical Research. 2023; 6(3): 168 - 180. 10.30714/j-ebr.2023.181
IEEE Ateş M,AKCEVIN A,Şal O,ER Z,TOSYA A "Measurement of primary hemostasis potential with platelet function analyzer to investigate the predictive effect on post-operative blood loss in cyanotic and acyanotic pediatric patients." Experimental Biomedical Research, 6, ss.168 - 180, 2023. 10.30714/j-ebr.2023.181
ISNAD Ateş, Mehmet Şanser vd. "Measurement of primary hemostasis potential with platelet function analyzer to investigate the predictive effect on post-operative blood loss in cyanotic and acyanotic pediatric patients". Experimental Biomedical Research 6/3 (2023), 168-180. https://doi.org/10.30714/j-ebr.2023.181
Sayfa Oluşturulma Tarihi
24-04-2024 8:29

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları